Spearhead Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-4,020
| Closed | -$342K | – | 217 |
|
|
2021
Q4 | $342K | Buy |
4,020
+48
| +1% | +$4.08K | 0.04% | 135 |
|
|
2021
Q3 | $381K | Sell |
3,972
-28
| -0.7% | -$2.69K | 0.05% | 129 |
|
|
2021
Q2 | $389K | Buy |
4,000
+595
| +17% | +$57.9K | 0.05% | 149 |
|
|
2021
Q1 | $331K | Buy |
3,405
+1,077
| +46% | +$105K | 0.05% | 140 |
|
|
2020
Q4 | $223K | Buy |
2,328
+142
| +6% | +$13.6K | 0.04% | 165 |
|
|
2020
Q3 | $210K | Buy |
2,186
+144
| +7% | +$13.8K | 0.04% | 178 |
|
|
2020
Q2 | $249K | Buy |
+2,042
| New | +$249K | 0.05% | 129 |
|